Pharmacologic characterization of the oxytocin receptor in human uterine smooth muscle cells
- 30 January 2000
- journal article
- Published by Wiley in British Journal of Pharmacology
- Vol. 129 (1) , 131-139
- https://doi.org/10.1038/sj.bjp.0702996
Abstract
[(3)H]-oxytocin was used to characterize the oxytocin receptor found in human uterine smooth muscle cells (USMC). Specific binding of [(3)H]-oxytocin to USMC plasma membranes was dependent upon time, temperature and membrane protein concentration. Scatchard plot analysis of equilibrium binding data revealed the existence of a single class of high-affinity binding sites with an apparent equilibrium dissociation constant (K(d)) of 0.76 nM and a maximum receptor density (B(max)) of 153 fmol mg(-1) protein. The Hill coefficient (n(H)) did not differ significantly from unity, suggesting binding to homogenous, non-interacting receptor populations. Competitive inhibition of [(3)H]-oxytocin binding showed that oxytocin and vasopressin (AVP) receptor agonists and antagonists displaced [(3)H]-oxytocin in a concentration-dependent manner. The order of potencies for peptide agonists and antagonists was: oxytocin>[Asu(1,6)]-oxytocin>AVP= atosiban>d(CH(2))(5)Tyr(Me)AVP>[Thr(4),Gly(7)]-oxytocin>dDAVP, and for nonpeptide antagonists was: L-371257>YM087>SR 49059>OPC-21268>SR 121463A>OPC-31260. Oxytocin significantly induced concentration-dependent increase in intracellular Ca(2+) concentration ([Ca(2+)](i)) and hyperplasia in USMC. The oxytocin receptor antagonists, atosiban and L-371257, potently and concentration-dependently inhibited oxytocin-induced [Ca(2+)](i) increase and hyperplasia. In contrast, the V(1A) receptor selective antagonist, SR 49059, and the V(2) receptor selective antagonist, SR 121463A, did not potently inhibit oxytocin-induced [Ca(2+)](i) increase and hyperplasia. The potency order of antagonists in inhibiting oxytocin-induced [Ca(2+)](i) increase and hyperplasia was similar to that observed in radioligand binding assays. In conclusion, these data provide evidence that the high-affinity [(3)H]-oxytocin binding site found in human USMC is a functional oxytocin receptor coupled to [Ca(2+)](i) increase and cell growth. Thus human USMC may prove to be a valuable tool in further investigation of the physiologic and pathophysiologic roles of oxytocin in the uterus. British Journal of Pharmacology (2000) 129, 131 - 139Keywords
This publication has 66 references indexed in Scilit:
- The Role of Mitogen-Activated Protein Kinase in Oxytocin-Induced Contraction of Uterine Smooth Muscle in Pregnant RatBiochemical and Biophysical Research Communications, 1996
- Characterization of SR 121463A, a highly potent and selective, orally active vasopressin V2 receptor antagonist.Journal of Clinical Investigation, 1996
- Treatment of Preterm Labor with the Oxytocin Antagonist AtosibanAmerican Journal of Perinatology, 1996
- 1-[1-[4-[(N-Acetyl-4-piperidinyl)oxy]-2- methoxybenzoyl]piperidin-4-yl]-4H-3,1- benzoxazin-2(1H)-one (L-371,257): a new, orally bioavailable, non-peptide oxytocin antagonist.Journal of Medicinal Chemistry, 1995
- Characterization of the human oxytocin receptor stably expressed in 293 human embryonic kidney cellsLife Sciences, 1995
- Oxytocin enhances myoepithelial cell differentiation and proliferation in the mouse mammary glandEndocrinology, 1993
- Oxytocin Gene Expression in Rat UterusScience, 1992
- Mechanism of action of the oxytocin antagonist 1‐deamino‐2‐dTyr‐(OEt)‐4‐Thr‐8‐Orn‐oxytocinBJOG: An International Journal of Obstetrics and Gynaecology, 1989
- Oxytocin receptors in rat oviductBiochemical and Biophysical Research Communications, 1975
- Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reactionBiochemical Pharmacology, 1973